A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
| Study Name | |
| A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | |
| ClinicalTrials.gov Identifier (if applicable) | |
| NCT05211323 | |
| Clinical Trial Category (check all that apply) | |
|
|
| Study Center | |
| Institution Name | |
| National Cancer Institute/ECOG-ACRIN Cancer Research Group | |
| Institution Address | |
| 5323 Harry Hines Blvd | |
| City | |
| Dallas | |
| State | |
| Texas | |
| Zip Code | |
| 75390 | |
| Country | |
| United States | |
| Study Contacts | |
| Principal Investigator | |
| David Hsieh | |
| P.I. Phone | |
| (214) 648-4180 | |
| P.I. Email | |
| david.hsieh@UTSouthwestern.edu | |
| Study Coordinator | |
| Ellen Siglinsky | |
| Study Coordinator Phone | |
| (214) 645-9684 | |
| Study Coordinator Email | |
| ellen.siglinsky@ |
|
| OVERVIEW – in layman’s terms (150 words max) | |
| This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) that cannot be removed by surgery (unresectable) or that may have spread from where it first started. | |
| Enrollment | |
| 80 | |
| Study Start Date | |
| 01/27/2022 | |
| Estimated Completion Date | |
| 01/01/2025 | |
| Financial Assistance is available to participants for travel, lodging, etc. | |
|
|